IBIO iBio, Inc.

NEUTRAL Impact: 3/10 Insider Cluster (1 insider)
Horizon days Filed Mar 19, 2026 Processed 2mo ago
Insider cluster: 3 insiders, $0.1M total
Latest settled — T+20d
IBIO ▼ -1.90% at T+20d
NEUTRAL call ✗ call lost -1.90% · α vs SPY -9.53% · entry $2.10 → $2.06
Next anchor: T+60d in 2d
Last close $1.73 (close Jun 8) · -17.62% from $2.10 entry
Entry anchored
Mar 18, 03:59 PM ET
via Databento tick
T+1d
-0.48%
call -0.48% · α +1.27%
$2.09
settled 3mo ago
T+5d
-17.14%
call -17.14% · α -14.93%
$1.74
settled 3mo ago
T+20d
-1.90%
call -1.90% · α -9.53%
$2.06
settled 8w ago
T+60d
call — · α —
in 2d

Price Chart

Loading chart...

Executive Summary

iBio's Chief Legal Officer, Marc Banjak, purchased 12,500 shares in the open market for approximately $20,531, marking a small but notable insider buy. This adds to recent insider buying activity, with three other purchases totaling $96K in the past 30 days.

Key Financial Metrics

Direction
buying
Total Value
$20.5K
Insiders
1

Actionable Insight

While the dollar amount is small and not immediately market-moving, the continued insider buying — especially by a C-suite officer — suggests confidence at a time when the company remains underfollowed and low-liquidity. Traders should monitor for additional purchases or catalysts such as clinical updates or partnerships.

Key Facts

  • Chief Legal Officer Marc Banjak purchased 12,500 shares at $1.6425 per share for a total of $20,531.25
  • This is an open-market purchase (Form 4 code 'P'), indicating direct confidence in the company
  • Total insider buying in the past 30 days now reaches $116,531
  • The transaction represents approximately 0.034% of the company's $60M market cap

Financial Impact

$20,531 in open-market purchases by a C-suite executive

insider ownershipmarket sentiment

Risk Factors

  • The transaction is minor in absolute and relative terms (<0.1% of market cap), limiting its significance
  • No accompanying financial or operational filing was provided, so no fundamental catalyst is evident

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (1 trades, 7d window)cluster-IBIO-1774641960079
9 reports for IBIO
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+20▲ +36.43%Feb 27, 2026
Filters
Rows
Reports for IBIO — sortable, filterable
Type Now
May 15, 2026
25d ago
3
NEUTRAL ★ 2/10
$1.47 $1.84▲ +25.17%▲ +24.21%$1.73 (+17.69%)
May 12, 2026
28d ago
Press Release
BEARISH ★ 6/10
$1.55 $1.50▲ +3.23%▲ +2.07%$1.73 (−11.61%)
May 8, 2026
4w ago
8-K
NEUTRAL ★ 2/10
$1.66 $1.42▼ −14.46%▼ −14.37%$1.73 (+4.22%)
Apr 8, 2026
8w ago
8-K
MIXED ★ 6/10
$2.24 $2.10▼ −6.25%▼ −9.77%$1.73 (−22.77%)
Mar 19, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$2.10 $1.74▼ −17.14%▼ −14.93%$1.73 (−17.62%)
Mar 19, 2026
11w ago
Insider Cluster
BULLISH ★ 5/10
$2.10 $1.74▼ −17.14%▼ −14.93%$1.73 (−17.62%)
Mar 16, 2026
12w ago
Press Release
MIXED ★ 6/10
$2.46 $2.08▼ −15.45%▼ −12.79%$1.73 (−29.67%)
Mar 9, 2026
13w ago
EFFECT
NEUTRAL ★ 3/10
$2.50 $2.39▼ −4.40%▼ −3.05%$1.73 (−30.80%)
Feb 27, 2026
14w ago
S-3
BEARISH ★ 7/10
$2.69 $2.50▲ +7.06%▲ +5.86%$1.73 (+35.69%)
Showing 9 of 9

US Market Status

Market Closed — Opens in 7h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access